CIViC Compass
Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.

CIViC Evidence Items

4766 evidence items indexed

Evidence Level Distribution

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline
BClinical — prospective trial or retrospective cohort study
CCase study — single case report or small case series
DPreclinical — in vitro or animal model data
EInferential — computational prediction or biological rationale

Gene × Evidence Type

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

PredictiveDiagnosticPrognosticFunctionalPredispos.Oncogenic
BCR::ABL132311
BRAF18642621
EGFR2481232
EML4::ALK64
ERBB21422
FLT355221
KIT10237
KRAS1594244
PIK3CA156164
PTEN5313121
TP5352401002
VHL52363515
Predictive:Links a variant to treatment response or resistance
Diagnostic:Supports or refutes a specific disease diagnosis
Prognostic:Informs disease progression or clinical outcome
Functional:Characterises the biological effect of a variant
Predisposing:Germline variant associated with cancer predisposition
Oncogenic:Characterises the variant's role in oncogenesis
LevelGeneVariantTypeDirectionSignificanceDiseaseDrugsSource
BKRASG12APredictiveSupportsResistanceLung AdenocarcinomaGefitinib,ErlotinibMarchetti et al., 2009
DCCND3LossPredictiveSupportsSensitivity/ResponseT-cell Lymphoblastic Leukemia/lymphomaPalbociclibSawai et al., 2012
CDDR2S768RPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaDasatinib,ErlotinibHammerman et al., 2011
CEGFRT790MPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaErlotinib,PemetrexedLi et al., 2014
CFGFR2::TACC3FusionPredictiveSupportsSensitivity/ResponseCholangiocarcinomaPazopanib,PonatinibBorad et al., 2014
CKITInternal DuplicationPredictiveSupportsSensitivity/ResponseMalignant Anus MelanomaImatinibHodi et al., 2008
DKITL576PPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaDasatinib,Nilotinib,ImatinibAntonescu et al., 2007
BKITV654APredictiveSupportsSensitivity/ResponseGastrointestinal Stromal TumorSunitinibPrenen et al., 2006
DPIK3CAE542KPredictiveSupportsSensitivity/ResponseBreast CancerSirolimusKang et al., 2005
DTP53R175HPredictiveSupportsSensitivity/ResponseBreast CancerDoxorubicinJackson et al., 2012
BTSC1Frameshift TruncationPredictiveSupportsSensitivity/ResponseInvasive Bladder Transitional Cell CarcinomaEverolimusIyer et al., 2012
BFLT3TKD MUTATIONPrognosticDoes Not SupportAcute Myeloid LeukemiaYamamoto et al., 2001
BIDH2MutationPrognosticDoes Not SupportAcute Myeloid LeukemiaThol et al., 2010
BIDH2R140PrognosticDoes Not SupportMyelodysplastic SyndromePatnaik et al., 2012
BKITExon 11 MutationPrognosticDoes Not SupportGastrointestinal Stromal TumorCorless et al., 2002
BKRASG12PrognosticDoes Not SupportLung Non-small Cell CarcinomaSchiller et al., 2001
BCCND1ExpressionPrognosticDoes Not SupportPoor OutcomeLung Non-small Cell CarcinomaGautschi et al., 2007
BPTENR233*PrognosticDoes Not SupportPoor OutcomeGlioblastomaCarico et al., 2012
BEGFRL858RPrognosticSupportsBetter OutcomeLung Non-small Cell CarcinomaDouillard et al., 2014
BIDH1R132PrognosticSupportsBetter OutcomeMalignant AstrocytomaDubbink et al., 2009
BIDH1R132PrognosticSupportsBetter OutcomeGlioblastomaBleeker et al., 2010
BIDH2R140PrognosticSupportsBetter OutcomeAcute Myeloid LeukemiaGreen et al., 2011
BSF3B1MutationPrognosticSupportsBetter OutcomeMyelodysplastic SyndromePapaemmanuil et al., 2011
BCCND1AmplificationPrognosticSupportsPoor OutcomeLung Non-small Cell CarcinomaGautschi et al., 2007
BCCND1ExpressionPrognosticSupportsPoor OutcomeLung Non-small Cell CarcinomaGautschi et al., 2007
BCDKN2APromoter HypermethylationPrognosticSupportsPoor OutcomeLung Non-small Cell CarcinomaBradly et al., 2012
BCDKN2APromoter HypermethylationPrognosticSupportsPoor OutcomeLung Non-small Cell CarcinomaBradly et al., 2012
BFLT3ITDPrognosticSupportsPoor OutcomeAcute Myeloid LeukemiaYamamoto et al., 2001
BIDH2R172KPrognosticSupportsPoor OutcomeAcute Myeloid LeukemiaGreen et al., 2011
BKITExon 11 MutationPrognosticSupportsPoor OutcomeGastrointestinal Stromal TumorTaniguchi et al., 1999
BKRASG12PrognosticSupportsPoor OutcomeMultiple MyelomaChng et al., 2008
BKRASG12PrognosticSupportsPoor OutcomeLung Non-small Cell CarcinomaMascaux et al., 2005
CPIK3CAE545KPredictiveSupportsResistanceColorectal CancerPanitumumab,CetuximabSartore-Bianchi et al., 2009
BTP53R175HPrognosticSupportsPoor OutcomeBreast CancerOlivier et al., 2006
BTP53R248QPrognosticSupportsPoor OutcomeBreast CancerOlivier et al., 2006
BTP53R248QPrognosticSupportsPoor OutcomeBreast CancerBerns et al., 1998
BTP53R248WPrognosticSupportsPoor OutcomeBreast CancerOlivier et al., 2006
BTP53MutationPrognosticSupportsPoor OutcomeBreast CancerBerns et al., 1998
BTP53R273CPrognosticSupportsPoor OutcomeBreast CancerOlivier et al., 2006
BTP53R273CPrognosticSupportsPoor OutcomeBreast CancerBerns et al., 1998
BTP53R273HPrognosticSupportsPoor OutcomeBreast CancerOlivier et al., 2006
BTP53R273HPrognosticSupportsPoor OutcomeBreast CancerBerns et al., 1998
BTP53R249PredictiveSupportsSensitivity/ResponseBreast CancerDoxorubicinBerns et al., 1998
BU2AF1Q157P/RPrognosticSupportsPoor OutcomeMyelodysplastic SyndromeWu et al., 2013
BU2AF1S34Y/FPrognosticSupportsPoor OutcomeMyelodysplastic SyndromeWu et al., 2013
DMEF2D::CSF1RFusionPredictiveSupportsSensitivity/ResponseAcute Lymphoblastic LeukemiaGW-2580,ImatinibLilljebjörn et al., 2014
BFOXP1AMPLIFICATIONDiagnosticSupportsPositiveDiffuse Large B-cell LymphomaLenz et al., 2008
DIGF2OverexpressionPredictiveDoes Not SupportSensitivity/ResponseProstate CancerLinsitinibVidal et al., 2015
DIGF2OverexpressionPredictiveSupportsSensitivity/ResponseProstate CancerCabazitaxel,Linsitinib,DocetaxelVidal et al., 2015
BAURKAEXPRESSIONPrognosticSupportsBetter OutcomeOvarian CarcinomaMendiola et al., 2009
Page 28 of 96
PreviousNext